Pharming Group NV (PHAR): Price and Financial Metrics


Pharming Group NV (PHAR): $7.32

-0.54 (-6.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PHAR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PHAR Stock Price Chart Interactive Chart >

Price chart for PHAR

PHAR Price/Volume Stats

Current price $7.32 52-week high $12.56
Prev. close $7.86 52-week low $6.71
Day low $7.10 Volume 4,500
Day high $8.20 Avg. volume 5,067
50-day MA $8.45 Dividend yield N/A
200-day MA $9.19 Market Cap 476.85M

Pharming Group NV (PHAR) Company Bio


Pharming Group NV is a biopharmaceutical company involved with the development, production and commercialization of human therapeutic proteins to be used in highly innovative therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage, and surgical/traumatic bleeding.


PHAR Latest News Stream


Event/Time News Detail
Loading, please wait...

PHAR Latest Social Stream


Loading social stream, please wait...

View Full PHAR Social Stream

Latest PHAR News From Around the Web

Below are the latest news stories about Pharming Group NV that investors may wish to consider to help them evaluate PHAR as an investment opportunity.

Indices - Pharming Group Lowered to Strong Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Pharming Group from a hold rating to a strong sell rating in a research note issued to investors on Tuesday morning, Zacks.com

Business Mag | February 9, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investor!

William White on InvestorPlace | February 2, 2022

Why Are Pharming Shares Trading Higher Today?

Pharming Group NV (NASDAQ: Full story available on Benzinga.com

Benzinga | February 2, 2022

Pharming announces positive results of Phase II/III pivotal clinical study of leniolisib for the treatment of activated PI3K delta syndrome

Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/NASDAQ: PHAR) announces positive results from the pivotal Phase II/III blinded randomized, placebo-controlled registration-enabling study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) also known as PASLI (p110δ-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency).

Yahoo | February 2, 2022

Pharming receives positive EMA decision on paediatric investigation plan (PIP) for leniolisib in Europe

Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that a positive decision has been made by the European Medicines Agency (EMA) on the Paediatric Investigation Plan (PIP) for leniolisib, a phosphoinositide 3-kinase (PI3K) inhibitor, currently in development for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS).

Yahoo | January 6, 2022

Read More 'PHAR' Stories Here

PHAR Price Returns

1-mo -18.66%
3-mo -14.59%
6-mo -15.08%
1-year -39.00%
3-year N/A
5-year N/A
YTD -18.12%
2021 -41.16%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7314 seconds.